French pharmaceutical giant Sanofi will buy U.S. partner Translate Bio, an mRNA therapeutics firm, in an effort to “unlock the potential of mRNA,”
French pharmaceutical giant Sanofi will buy Massachusetts-based Translate Bio, an mRNA therapeutics firm, in an effort to “unlock the potential of mRNA,” the company said Tuesday, a month after it announced an almost $500 billion annual investment into the technology underpinning the highly successful Covid-19 vaccines made by Pfizer and Moderna.
Paul Hudson, Sanofi’s chief executive, said the acquisition would allow it to ramp up existing projects and explore “additional opportunities in the fast-evolving” space. “Our goal is to unlock the potential of mRNA in other strategic areas such as immunology, oncology, and rare diseases in addition to vaccines,” Hudson said.
Sanofi and Translate Bio, which began collaborating in June 2018, have two mRNA vaccines for Covid-19 and and influenza in early stage clinical trials, with results expected in the third and fourth quarters of 2021 respectively. Translate Bio also has possible treatments for cystic fibrosis and other rare lung diseases in its early stage pipeline and is exploring how its mRNA technology can be applied to liver diseases and cancer. The deal was approved unanimously by boards of directors at both companies and will “fast track” the establishment of Sanofi’s.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Sanofi to Buy Translate BioBy Kim Richters French healthcare major Sanofi has agreed to acquire Translate Bio Inc. in a deal that gives the mRNA-therapeutics company a total equity...
Consulte Mais informação »
Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA TechI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Consulte Mais informação »
Sanofi M&A punt soothes France’s Covid-19 shameThe $131 bln drugmaker bought U.S-listed Translate Bio for $3 bln. CEO Paul Hudson gets a leg up in hot mRNA technology, which trounced the French group’s traditional vaccines during the pandemic. Shareholder returns look distant, but the cost of standing still may be higher.
Consulte Mais informação »
Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA TechI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Consulte Mais informação »
Sanofi to Buy Translate BioBy Kim Richters French healthcare major Sanofi has agreed to acquire Translate Bio Inc. in a deal that gives the mRNA-therapeutics company a total equity...
Consulte Mais informação »
Square makes ‘game-changing’ play for Afterpay in big bet on buy-now pay-later waveSquare Inc. plans to acquire buy-now pay-later (BNPL) operator Afterpay Ltd. in what one analyst sees as a 'game-changing' $29 billion deal that will help...
Consulte Mais informação »